ArticleScientific reports2016
Potential Dual Role of Eugenol in Inhibiting Advanced Glycation End Products in Diabetes: Proteomic and Mechanistic Insights.
Article in Scientific reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 1 synthesis or guideline pooled it, 139 citations in OpenAlex.
- Efficacy of cinnamon supplementation on glycolipid metabolism in T2DM diabetes: A meta-analysis and systematic review.Frontiers in physiology · 2022Pooled it
- Trial
- N-Acetyl Cysteine Mitigates d-Ribose-Induced Protein Glycation and Aggregation Through Multiple Protective Mechanisms.IUBMB life · 2026Article
- Piper auritum (Kunth) Fungal Endophytes: A Source of Metabolites to Inhibit the Formation of Advanced Glycation End Products.Chemistry & biodiversity · 2025Article
- Optimization of Supplemental LED Spectral Quality and Light Dose for Enhancing Biomass and Essential Oil Yield ofMolecules (Basel, Switzerland) · 2025Article
- Chemical profile of essential oil from Pimenta racemosa leaves, antioxidant potential, and its enzyme inhibitory properties.Scientific reports · 2025Article
- Article
- The protective roles of eugenol on type 1 diabetes mellitus through NRF2-mediated oxidative stress pathway.eLife · 2025Article
- Variation of the essential oil components of Citrus aurantium leaves upon using different distillation techniques and evaluation of their antioxidant, antidiabetic, and neuroprotective effect against Alzheimer's disease.BMC complementary medicine and therapies · 2024Article
- Effects of Dietary Supplement of Basil Extract on Biochemical and Immunological Parameters and Growth Performance inAquaculture nutrition · 2024Article
- Article
- Novel Fluorometric Assay of Antiglycation Activity Based on Methylglyoxal-Induced Protein Carbonylation.Antioxidants (Basel, Switzerland) · 2023Article
- Anti-Inflammatory Properties of Eugenol in Lipopolysaccharide-Induced Macrophages and Its Role in Preventing β-Cell Dedifferentiation and Loss Induced by High Glucose-High Lipid Conditions.Molecules (Basel, Switzerland) · 2023Article
- Network pharmacology based anti-diabetic attributes of bioactive compounds fromSaudi journal of biological sciences · 2023Article
- Protective Effects of Medicinal Plant-Based Foods against Diabetes: A Review on Pharmacology, Phytochemistry, and Molecular Mechanisms.Nutrients · 2023Review
- Black Pepper (Antioxidants (Basel, Switzerland) · 2023Article
- Multi-Targeting Neuroprotective Effects ofInternational journal of molecular sciences · 2023Article
- Design and Investigation of New Water-Soluble Forms of α-Tocopherol with Antioxidant and Antiglycation Activity Using Amphiphilic Copolymers ofPharmaceutics · 2023Article
- Antioxidant, Antibacterial, Enzyme Inhibitory, and Anticancer Activities and Chemical Composition ofPharmaceuticals (Basel, Switzerland) · 2022Article
- The clove (Syzygium aromaticum) genome provides insights into the eugenol biosynthesis pathway.Communications biology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Medicinally important genus Ocimum harbors a vast pool of chemically diverse metabolites. Current study aims at identifying anti-diabetic candidate compounds from Ocimum species. Major metabolites in O. kilimandscharicum, O. tenuiflorum, O. gratissimum were purified, characterized and evaluated for anti-glycation activity. In vitro inhibition of advanced glycation end products (AGEs) by eugenol was found to be highest. Preliminary biophysical analysis and blind docking studies to understand eugenol-albumin interaction indicated eugenol to possess strong binding affinity for surface exposed lysines. However, binding of eugenol to bovine serum albumin (BSA) did not result in significant change in secondary structure of protein. In vivo diabetic mice model studies with eugenol showed reduction in blood glucose levels by 38% likely due to inhibition of α-glucosidase while insulin and glycated hemoglobin levels remain unchanged. Western blotting using anti-AGE antibody and mass spectrometry detected notably fewer AGE modified peptides upon eugenol treatment both in vivo and in vitro. Histopathological examination revealed comparatively lesser lesions in eugenol-treated mice. Thus, we propose eugenol has dual mode of action in combating diabetes; it lowers blood glucose by inhibiting α-glucosidase and prevents AGE formation by binding to ε-amine group on lysine, protecting it from glycation, offering potential use in diabetic management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.